Molecular Drug Imaging: $^{89}\text{Zr}-\text{Bevacizumab}$ PET in Children with Diffuse Intrinsic Pontine Glioma

Marc H. Jansen*1, Sophie E.M. Veldhuijzen van Zanten*1, Dannis G. van Vuurden1, Marc C. Huisman2, Danielle J. Vugts2, Otto S. Hoekstra2, Guus A. van Dongen2, and Gert-Jan L. Kaspers1

1Pediatric Oncology/Hematology, Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands; and 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

The need for predictors to guide therapy in individual patients applies to the entire field of pediatric oncology but, in particular, to malignant brain tumors. One of the most challenging brain tumors in children is diffuse intrinsic pontine glioma (DIPG), a lethal childhood malignancy of the brain stem comprising 10% of all pediatric central nervous system tumors (1). DIPG tumors are resistant to all kinds of systemic therapies, including targeted agents, and hardly any patient survives beyond 2 y from diagnosis (2,3). One hypothesis for therapy failure is that drugs actually do not reach the tumors, as in most DIPG tumors at diagnosis MRI shows little or no gadolinium contrast enhancement, suggesting an intact blood–brain barrier for large molecules (4). Molecular drug imaging may help in the investigation of this hypothesis; however, despite a recent boost in molecular drug imaging in adults, no immuno-PET imaging studies have yet been performed in children (5).

Recent messenger RNA profiling studies revealed overexpression of the proangiogenic vascular endothelial growth factor (VEGF) in DIPG compared with the normal brain and compared with adult high-grade glioma, a result that makes proangiogenic VEGF a potential drug target (6,7). The biologic activity of VEGF can be neutralized by bevacizumab, a recombinant humanized monoclonal antibody. The potential of bevacizumab in DIPG is being studied in several trials (clinicaltrials.gov: NCT01182350; Trialregister.nl: NTR2391), but few trials have been published (8–10). The overall survival outcome in these DIPG trials was as poor as in patients receiving standard treatment (8,9), but individual patients with significant responses and prolonged survival after bevacizumab treatment have been reported (10,11). Hence, the challenge is to identify patients who will benefit from bevacizumab treatment.

$^{89}\text{Zr}$-labeled bevacizumab PET imaging may help in assessment of the inter- and intrapatient heterogeneity of drug biodistribution in vivo, thereby predicting the presence or absence of a response in patients subsequently treated with bevacizumab. Studies in both mice and adult patients confirmed that $^{89}\text{Zr}$-bevacizumab PET imaging was feasible and able to reveal bevacizumab accumulation in VEGF-positive tumors (7,12–14). In addition, in adult renal cancer tumors, $^{89}\text{Zr}$-bevacizumab uptake was correlated with a response to bevacizumab treatment (13). The results of our preclinical research with $^{89}\text{Zr}$-bevacizumab in mice suggested poor bevacizumab uptake in intracranial tumors; using pontine, striatal, and subcutaneous glioma mouse models, we found no significant uptake of $^{89}\text{Zr}$-bevacizumab in intracranial tumors at any stage of the disease or in the normal nonneoplastic surrounding brain in any of the tumor models used (7). In contrast, a high level of accumulation of $^{89}\text{Zr}$-bevacizumab was observed in the subcutaneous glioma xenograft. Therefore, poor bevacizumab distribution in the brain seemed to be a major issue, but we also observed a significantly lower level of VEGF expression in intracranial tumors than in the subcutaneous glioma xenograft.

**Key Words:** brain stem neoplasm; PET; $^{89}\text{Zr}$-bevacizumab; pharmacokinetics

J Nucl Med 2017; 58:711–716
DOI: 10.2967/jnumed.116.180216
As a first step in investigating the clinical utility of immuno-PET in this setting, we performed a pilot study to investigate whether bevacizumab can reach tumors in children with DIPGs by measuring the tumor uptake of $^{89}$Zr-bevacizumab. In addition, we assessed the optimal time for PET imaging, evaluated the biodistribution and radiation dosimetry of $^{89}$Zr-bevacizumab, and ascertained the safety and tolerability of scanning procedures without anesthesia.

MATERIALS AND METHODS

Study Population

The study was conducted at VU University Medical Center, Amsterdam, The Netherlands. DIPG patients who were 4–18 y old and had completed radiotherapy (the standard DIPG therapy) at least 2 wk earlier were eligible. Patients with a known hypersensitivity to humanized monoclonal antibodies were excluded, as were those previously treated with bevacizumab or any other anti-VEGF agent. To reduce patient burden, PET-related blood sampling and the use of anesthetics were not allowed. The latter was the reason for the minimum age of 4 y, as children younger than 4 y were not expected to complete a PET scan with no movement artifacts without the use of anesthesia.

For all subjects, both parents signed a written informed consent form. In addition, all subjects who were at least 12 y old signed a written informed consent form. The study (registered as NTR3518 in The Netherlands National Trial Register) was approved by the Dutch Central Committee on Research Involving Human Subjects and the Institutional Review Board of VU University Medical Center and was performed in accordance with the Declaration of Helsinki.

To determine the optimal time for scanning (72 or 144 h after injection), we aimed to include at least 5 patients with visible tumor uptake of $^{89}$Zr-bevacizumab. These postinjection times were based on previous research in mice and clinical studies in adults with $^{89}$Zr-bevacizumab (7,12,14).

$^{89}$Zr-Bevacizumab Labeling, Infusion, and PET Procedures

The production and purification of $^{89}$Zr and its coupling to bevacizumab were performed in accordance with good manufacturing practice at VU University Medical Center. The labeling process as well as quality controls were described previously (15–17), and the results were similar to those described by Bahce et al. (14). The administered dose of $^{89}$Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) was 1% of the therapeutic bevacizumab dose in humans.

Patients were imaged with a whole-body Philips Gemini TF64 PET/CT scanner (18). Each PET scan was preceded by a low-dose CT scan with routinely applied settings. The CT scan was followed by a 10-min static PET/CT scan covering the brain and a whole-body PET scan (4 min per bed position covering the neck to the upper legs and 1 min covering the legs). PET scans were performed at 1, 72, and 144 h after injection. Patients were clinically observed for 3 h after injection to check for allergic reactions, and they were instructed to contact the hospital in case of later adverse events. All patients underwent T1-weighted pre- and postgadolinium MRI and T2-weighted MRI without anesthesia (Siemens Sonata 1.5-T MRI scanner) within a 2-wk period before PET.

Image Analysis

Visual analysis of the PET scans was first performed without knowledge of the MRI results. Focal uptake exceeding the local background was considered to be a positive result. Volumes of interest were generated manually for tumors and metastases with enhanced tracer uptake and for the blood pool (1.6 mL in the aortic arch), liver, kidneys, spleen, lungs, and bone (vertebrae). SUVs were calculated as the decay-corrected activity concentration (kBq/mL) per injected dose (MBq) per body weight (kg). PET images of the brain were coregistered with gadolinium-enhanced T1-weighted MR images to enable comparison of postcontrast MR images with PET images. T2-weighted MRI was used to determine whether $^{89}$Zr-bevacizumab uptake was present in the whole tumor or focally. Whole-body dosimetry was performed with OLINDA software (19). This dosimetry model takes into account an age-dependent weight factor.

Statistics

Statistical analyses were performed with SPSS version 19 (IBM SPSS). For correlations between SUV$_{\text{mean}}$ ratios and time after injection, a nonparametric correlation test (Kendall $\tau_b$) was used.

RESULTS

Population: Safety and Feasibility

We included 7 patients with primary DIPG tumors; 1 patient had metastatic disease in the spinal cord and subependymal space, and another had tumor extension in the facial nerve. The baseline characteristics of the patients are shown in Table 1. The median age was 8 y (range, 6–17 y), and all patients had been pretreated with radiotherapy (in combination with gemcitabine for 3 patients and in combination with temozolomide for 1 patient). No adverse events were observed after injection of $^{89}$Zr-bevacizumab, and all patients tolerated the scans and related procedures well. The duration of the whole-body PET scans (including the brain) ranged from 40 to 50 min. All PET and MR images were of good quality and had no movement artifacts.

$^{89}$Zr-Bevacizumab Uptake in DIPG

The PET scans of 5 patients showed focally enhanced $^{89}$Zr-bevacizumab accumulation in their primary DIPG tumors (tumor transverse size range on MRI, 25–37 mm), whereas the PET scans for 2 patients did not show $^{89}$Zr-bevacizumab accumulation (tumor transverse size range on MRI, 36–39 mm) (Figs. 1C and 1E). The results of all tumor PET scans were negative at 1 h after injection and became positive as of 72 h after injection (Fig. 2A). In none of the patients was $^{89}$Zr-bevacizumab uptake present throughout the entire tumor, as depicted by T2-weighted MRI. For example, in the T2-weighted image (Fig. 1B), $^{89}$Zr-bevacizumab uptake was concentrated on the lower right side of the tumor, but the tumor extended into the whole pons. There was no visually detectable $^{89}$Zr-bevacizumab uptake in healthy brain tissue in any patient.

Tumor uptake of the tracer among patients was heterogeneous, with tumor SUVs ranging from 1.0 to 5.3 and from 1.0 to 6.7 at 72 and 144 h after injection, respectively (Fig. 2B). Five DIPG tumors showed focal areas of modest to strong contrast enhancement on gadolinium-enhanced T1-weighted MRI (Fig. 1). Coregistration of PET/MR images revealed focal $^{89}$Zr-bevacizumab uptake in these contrast-enhanced areas in 4 of 5 DIPG tumors. For 1 tumor with an area of gadolinium contrast enhancement (transverse enhancement size, 13 mm), the PET results were negative (Fig. 1C). In 1 DIPG tumor, the area of $^{89}$Zr-bevacizumab uptake on PET was not in an area of gadolinium contrast enhancement (Fig. 1D). SUVs in gadolinium-positive tumors varied widely (Table 1).

In 1 DIPG patient, 11 metastases were observed, and the PET results for all of them were positive (Fig. 3). The 2 largest metastases were in the spinal cord at the C1 level and in the subependymal space (volumes of 2.0 and 1.2 mL, respectively); the SUV$_{\text{mean}}$ for these metastases were 2.4 and 6.5 at 72 h after injection and 2.5
and 7.2 at 144 h after injection, respectively. In 1 patient, extension of the tumor in the facial nerve was seen on T2-weighted MRI, but there was no visually detectable PET signal.

**Optimal Moment of Scanning and Dosimetry**

There was no significant difference in the SUV means for the 5 tumors with positive PET results at 72 and 144 h after injection (Fig. 2B). Because blood-pool activity declined over time, tumor–to–blood-pool SUV ratios were positively correlated with time after injection ($P = 0.045$) (Fig. 2C).

Whole-body PET evaluation revealed that organ uptake of $^{89}$Zr-bevacizumab among patients was, in contrast to that in tumors, quite homogeneous; uptake was highest in the liver and then in the kidneys, spleen, lungs, and vertebrae (Fig. 4). The mean effective dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq) (Table 2).

**DISCUSSION**

There is an urgent need to predict the potential of a drug before therapy in children with brain tumors. In this first (to our knowledge) immuno-PET imaging study of pediatric oncology patients, we performed $^{89}$Zr-bevacizumab PET imaging of children with DIPG and showed that the procedure is feasible without the use of anesthetics from the age of 6 y. We observed inter- and intra-tumoral heterogeneity of $^{89}$Zr-bevacizumab uptake in 5 of 7 patients with DIPG, whereas the normal brain showed no uptake at all. Two of 7 primary tumors showed high-level but focal uptake, whereas $^{89}$Zr-bevacizumab was not detectable at all in 2 DIPG tumors. The optimal time for scanning was 144 h after injection, as the tumor–to–blood-pool SUV ratios increased.

---

**TABLE 1**

Baseline Characteristics and Scanning Results

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Weight (kg)</th>
<th>Metastases or tumor extension</th>
<th>Treatment before PET study</th>
<th>$^{89}$Zr dose (MBq)</th>
<th>Adverse events</th>
<th>Tumor transverse diameter (mm)</th>
<th>Gadolinium contrast enhancement on MRI</th>
<th>Tumor uptake of $^{89}$Zr-bevacizumab</th>
<th>Tumor SUV 72 h after injection</th>
<th>Tumor SUV 144 h after injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>6</td>
<td>33</td>
<td>None</td>
<td>RT</td>
<td>30.7</td>
<td>None</td>
<td>Small nodular</td>
<td>Yes</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>17</td>
<td>55</td>
<td>None</td>
<td>RT and gemcitabine</td>
<td>37.1</td>
<td>None</td>
<td>37 Ring</td>
<td>Yes</td>
<td>5.3</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>7</td>
<td>28</td>
<td>None</td>
<td>RT</td>
<td>24.2</td>
<td>None</td>
<td>36 Ring</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>8</td>
<td>30</td>
<td>None</td>
<td>RT</td>
<td>25.6</td>
<td>None</td>
<td>33 Patchy</td>
<td>Yes*</td>
<td>0.9</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>11</td>
<td>37</td>
<td>None</td>
<td>RT and gemcitabine</td>
<td>31.2</td>
<td>None</td>
<td>39 No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>13</td>
<td>44</td>
<td>Leptomeningeal and arachnoid metastases</td>
<td>RT and gemcitabine</td>
<td>34.7</td>
<td>None</td>
<td>32 Patchy</td>
<td>Yes</td>
<td>4.7</td>
<td>4.6</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>15</td>
<td>65</td>
<td>Tumor extension to nVII</td>
<td>RT and temozolomide</td>
<td>36.7</td>
<td>None</td>
<td>37 Ring</td>
<td>Yes</td>
<td>1.5</td>
<td>1.9</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>57%</td>
<td>M</td>
<td>11†</td>
<td>37†</td>
<td></td>
<td>31.5†</td>
<td>34.1†</td>
<td>2.7†</td>
<td></td>
<td>3.1†</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PET uptake was in area without gadolinium contrast enhancement.
†Median.
‡Mean.
RT = radiotherapy; nVII = facial nerve.
significantly over time. Therefore, we suggest the use of a single PET/CT scan at 144 h after injection in future studies.

The $^{89}$Zr-bevacizumab uptake pattern in all tumors was focal; interestingly, 4 of 5 tumors showed significant $^{89}$Zr-bevacizumab uptake only within MRI contrast-enhanced areas. Gadolinium uptake in the brain is associated with degradation of the blood–brain barrier; thus, when gadolinium–DPTA, with an average molecular weight of 545 kDa, is able to pass the blood–brain barrier, other large molecules, such as bevacizumab (149 kDa), may be able to pass as well—although blood–brain barrier permeability is, of course, dependent on more than molecular weight alone. In addition, contrast-enhanced “leaky” tumors have been associated with a higher level of local VEGF expression (20). However, we observed high variability in the level of $^{89}$Zr-bevacizumab uptake in gadolinium-enhanced areas (from intense to absent $^{89}$Zr-bevacizumab uptake), suggesting large differences in local VEGF expression among DIPG tumors. Moreover, 1 tumor showed $^{89}$Zr-bevacizumab uptake in an area without gadolinium contrast enhancement. Unfortunately, we were not able to validate VEGF expression in tissue.
as biopsies are not done routinely in DIPG patients. At least the clear differences in SUVs among gadolinium-enhanced tumors (reflecting differences in local drug uptake) and the presence of drug uptake in tumor areas without gadolinium contrast enhancement suggested that MRI alone is insufficient to predict the tumor accumulation of large molecules such as bevacizumab and that immuno-PET is of additional value.

We realize that the influence of radiotherapy is important. In our preclinical study with nonirradiated DIPG mouse models, we observed poor uptake of $^{89}$Zr-bevacizumab in intracranial tumors (7). In the present study, the fact that the patients had completed radiotherapy at least 2 wk earlier may have induced a temporary disruption of the blood–brain barrier as well as increased VEGF expression via the mitogen-activated protein kinase pathway (21). We expected that DIPG patients would be more eligible for bevacizumab treatment after radiotherapy and that the effect on blood–brain barrier integrity would dissipate with increasing time after radiotherapy. Therefore, ideally, scans should be performed before, during, and after radiotherapy in each patient to determine the susceptibility of tumors to bevacizumab over time.

More studies are needed to show the correlation of tumor uptake of $^{89}$Zr-bevacizumab and the response to treatment in DIPG patients. In adults with renal cell carcinoma, it has been shown that a high level of baseline $^{89}$Zr-bevacizumab uptake in tumors before treatment is positively associated with time to progression in bevacizumab-treated patients (13). A difficulty in performing such a study with DIPG patients is that current DIPG trials involve multiagent therapy regimens. The finding that bevacizumab can reduce the penetration of other drugs into tumors (22,23) underlines the need for labeled-drug imaging in this multiagent setting. On the other hand, in contrast to single-agent settings, multiagent therapy may confound the association of the imaging biomarker and outcome—so that clinical validation of this immuno-PET method as a predictive biomarker of the response to therapy requires larger datasets. However, because immuno-PET allows for international application (long physical half-life of $^{89}$Zr; relatively simple, centrally or locally performed radiochemistry), we suggest (on the basis of the data from the present pilot study) the inclusion of this method in future international DIPG clinical trials. Furthermore, molecular imaging data from different trials could be included in the recently established SIOPE DIPG Registry to enable comparison of results.

Whole-body molecular drug imaging can help to predict organ-related toxicity. These data are particularly important in children because drugs developed to target overexpressed cancer-specific signal proteins (such as VEGF) also target tissues in which these proteins are expressed during children’s development. In the present study, the whole-body $^{89}$Zr-bevacizumab biodistribution revealed a relatively high level of organ uptake in the liver and then in the blood, kidneys, lungs, and bone. These results are comparable to the results of the 2 $^{89}$Zr-bevacizumab clinical trials in adults and correspond to the results of toxicity trials with bevacizumab in children; in these trials, hypertension, bleeding, elevation of the aspartate aminotransferase level, and proteinuria were reported as the main side effects (13,14,24). We observed moderate bone uptake, but osteonecrosis is a rarely reported symptom in bevacizumab-treated children (1%). Whether $^{89}$Zr-bevacizumab uptake also correlates with long-term organ or bone toxicity needs to be addressed in long-term follow-up studies of children treated with bevacizumab.

The mean effective dose in the present study was slightly higher than doses of $^{89}$Zr-labeled compounds in studies with adults (25); this finding likely was due to the age-dependent weight factors in the dosimetry models. In the present study, the 29-mSv radiation burden of immuno-PET (including 3 low-dose total-body CT scans) for an average DIPG patient (25 kg) was considerable, although in future studies the radiation dose will be reduced to 22 mSv because only 1 PET/CT (low-dose) scan of the brain will be performed. However, the possible benefits may outweigh the risks, especially in light of the poor prognosis (2-y survival of <10%) for patients with DIPG.

**CONCLUSION**

In the present study, we used immuno-PET imaging for pediatric cancer patients. The procedure was found to be safe and feasible in children without the use of anesthetics, and the optimal time for scanning was 144 h after injection. Clear differences in $^{89}$Zr-bevacizumab uptake among DIPG tumors were observed, with 2 tumors showing no uptake at all. Interestingly, 4 of 5 tumors showed significant $^{89}$Zr-bevacizumab uptake on PET within MRI.

---

**TABLE 2**

Absorbed Dose and Effective Dose for Individual Subjects

<table>
<thead>
<tr>
<th>Patient</th>
<th>WB ROI</th>
<th>Kidneys</th>
<th>Liver</th>
<th>Lungs</th>
<th>Spleen</th>
<th>Bone marrow</th>
<th>RoB</th>
<th>MIRD age (y)</th>
<th>Sex</th>
<th>Effective dose (mSv/MBq)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>94.3</td>
<td>1.8</td>
<td>12.9</td>
<td>6.5</td>
<td>0.8</td>
<td>2.1</td>
<td>70.3</td>
<td>5</td>
<td>F</td>
<td>1.37</td>
</tr>
<tr>
<td>2</td>
<td>77.7</td>
<td>1.5</td>
<td>12.6</td>
<td>9.1</td>
<td>1.4</td>
<td>4.5</td>
<td>48.6</td>
<td>15</td>
<td>F</td>
<td>0.57</td>
</tr>
<tr>
<td>3</td>
<td>97.9</td>
<td>1.2</td>
<td>10.5</td>
<td>7.9</td>
<td>0.6</td>
<td>2.8</td>
<td>74.8</td>
<td>5</td>
<td>M</td>
<td>1.43</td>
</tr>
<tr>
<td>4</td>
<td>98.2</td>
<td>1.7</td>
<td>11.1</td>
<td>7.5</td>
<td>0.9</td>
<td>2.9</td>
<td>74.1</td>
<td>10</td>
<td>M</td>
<td>0.93</td>
</tr>
<tr>
<td>5</td>
<td>107.0</td>
<td>1.3</td>
<td>11.0</td>
<td>7.7</td>
<td>0.8</td>
<td>2.9</td>
<td>83.3</td>
<td>10</td>
<td>M</td>
<td>0.99</td>
</tr>
<tr>
<td>6</td>
<td>115.2</td>
<td>1.9</td>
<td>13.2</td>
<td>8.0</td>
<td>1.1</td>
<td>3.5</td>
<td>87.6</td>
<td>15</td>
<td>F</td>
<td>0.73</td>
</tr>
<tr>
<td>7</td>
<td>109.3</td>
<td>2.0</td>
<td>8.5</td>
<td>6.2</td>
<td>4.1</td>
<td>2.7</td>
<td>85.7</td>
<td>15</td>
<td>M</td>
<td>0.73</td>
</tr>
<tr>
<td>Total (median)</td>
<td>98.2</td>
<td>1.7</td>
<td>11.1</td>
<td>7.7</td>
<td>0.9</td>
<td>2.9</td>
<td>74.8</td>
<td></td>
<td></td>
<td>0.9</td>
</tr>
</tbody>
</table>

**WB** = whole body; **ROI** = region of interest; **RoB** = remainder of body.
contrast-enhanced areas. However, we observed high variability in SUVs in these contrast-enhanced areas, suggesting differences in local VEGF expression, and we observed positive PET results in a non–gadolinium-enhanced area in 1 patient. Therefore, MRI alone seems to be insufficient for predicting drug accumulation in tumors. The results suggest that the addition of $^{89}$Zr-bevacizumab PET imaging may be helpful in the selection of potential candidates for bevacizumab treatment of DIPG because this procedure assesses both target availability and drug accessibility of the tumor.

DISCLOSURE

This DIPG study was funded by the Semmy Foundation (Stichting Semmy) and the Egbers Foundation (Egbers Stichting). The Semmy Foundation and the Egbers Foundation, which fund DIPG research at VU University Medical Center, had no role in the study or preparation of this article. No other potential conflict of interest relevant to this article was reported.

REFERENCES

Molecular Drug Imaging: $^{89}$Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma

Marc H. Jansen, Sophie E.M. Veldhuijzen van Zanten, Dannis G. van Vuurden, Marc C. Huisman, Danielle J. Vugts, Otto S. Hoekstra, Guus A. van Dongen and Gert-Jan L. Kaspers

Published online: October 20, 2016.  
Doi: 10.2967/jnumed.116.180216

This article and updated information are available at:  
[http://jnm.snmjournals.org/content/58/5/711](http://jnm.snmjournals.org/content/58/5/711)

Information about reproducing figures, tables, or other portions of this article can be found online at:  
[http://jnm.snmjournals.org/site/misc/permission.xhtml](http://jnm.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNM can be found at:  
[http://jnm.snmjournals.org/site/subscriptions/online.xhtml](http://jnm.snmjournals.org/site/subscriptions/online.xhtml)